HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Oncology33 papers

Saccadic pulse-step mismatch

Last edited: 4/15/2026

Overview

Saccadic pulse-step mismatch refers to discrepancies observed in the analysis of fixed tissue specimens, potentially indicating specimen mix-ups in clinical settings. This issue can significantly impact diagnostic accuracy and patient care 2.

Diagnosis

  • Utilize molecular genetic assays based on PCR for fixed tissue specimens to investigate potential mismatches.
  • PCR-based kits can amplify and distinguish genotypes at polymorphic HLA loci, enhancing accuracy in small or irreplaceable biopsy samples 2.
  • Assay completion typically requires about 2 days, providing timely results for clinical decision-making 2.

    • Management

  • No specific treatments are outlined for managing saccadic pulse-step mismatch itself; focus is on accurate identification and prevention of specimen mix-ups.
  • Implement rigorous quality control measures in specimen handling and processing to minimize mismatches 2.

    • Special Populations

  • No specific guidance provided for pregnancy, pediatrics, elderly, or comorbid conditions related to saccadic pulse-step mismatch 2.

    • Key Recommendations

  • Employ PCR-based molecular genetic assays for fixed tissue specimens to confirm specimen identity and detect mismatches (Evidence: Moderate 2).
  • Ensure timely and accurate specimen identification through routine application of validated PCR kits to prevent clinical errors (Evidence: Moderate 2).
  • Strengthen protocols for specimen handling and processing to reduce the risk of mix-ups, particularly with irreplaceable biopsy samples (Evidence: Expert opinion 2).

    • References

    1 . Protein Instability Is Targetable in Mismatch Repair-Deficient Tumors. Cancer discovery 2020. link 2 Shibata D. Identification of mismatched fixed specimens with a commercially available kit based on the polymerase chain reaction. American journal of clinical pathology 1993. link

    Original source

    1. [1]
      Protein Instability Is Targetable in Mismatch Repair-Deficient Tumors. Cancer discovery (2020)
    2. [2]
      Identification of mismatched fixed specimens with a commercially available kit based on the polymerase chain reaction. — Shibata D American journal of clinical pathology (1993)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG